In pre-clinical tumor models, HB-0036 substantially improves tumor control and is associated with favorable anti-tumor signatures, including the reduced infiltration of neutrophils, lower abundance of TIGIT+ T cells, and increased production of IFN-γ by TILs, when compared to combination therapy with the two parental antibodies [107]. The gene discussed is TIGIT; the disease is neoplasm.